Stack Overview

One of the most common questions about the BPC-157 and TB-500 healing stack is about dosage. That question is understandable, but it also requires a careful answer, because the reality is more nuanced than most online sources suggest.

BPC-157 is a 15-amino-acid peptide derived from a protein found in human gastric juice. TB-500 is a synthetic peptide replicating the active region of Thymosin Beta-4, a protein involved in cell migration and tissue repair . Both have extensive preclinical research supporting their tissue-healing properties, but no regulatory body has established standardized dosing for either peptide in humans.

What follows is an educational overview of the factors that influence dosing decisions. This is not a dosing guide and should not be used to self-prescribe. Your physician is the only appropriate source for your specific dosing protocol.

Why These Work Together

Dosing for a peptide stack is more complex than dosing for a single compound because you are working with two biologically active substances that operate through different mechanisms.

BPC-157 promotes healing through angiogenesis (new blood vessel formation), nitric oxide system modulation, and growth factor receptor upregulation . TB-500 works primarily through actin regulation, promoting cell migration to injury sites and supporting structural protein organization .

Because their mechanisms are complementary, the dosing rationale is not simply additive. A physician designing a protocol for this stack must consider how each peptide's activity might influence the other's effectiveness, the total biological load on the patient, and the specific tissue targets involved.

Factors That Influence Dosing

No two patients receive identical protocols when working with a qualified physician. The following factors typically influence how a provider approaches dosing for this stack.

Body Weight and Composition

Peptide dosing often scales with body weight, though the relationship is not always linear. A larger individual may require different amounts than a smaller one to achieve comparable tissue concentrations. Body composition (lean mass vs. fat mass) can also influence peptide distribution and bioavailability.

Nature and Severity of the Condition

An acute sports injury, a chronic tendinopathy, and a post-surgical recovery scenario each present different healing challenges. The tissue type involved, the extent of damage, the duration of the condition, and the presence of complicating factors (such as poor blood supply to the area) all factor into dosing decisions.

Administration Route

BPC-157 can be administered subcutaneously, intramuscularly, or orally. TB-500 is typically administered subcutaneously. The route of administration affects bioavailability, which in turn affects the amount needed to reach therapeutic tissue concentrations .

Oral BPC-157, for example, may be preferred for gastrointestinal targets, while subcutaneous injection near an injury site may be chosen for localized musculoskeletal applications.

Phase of Treatment

Practitioners commonly distinguish between different phases of a protocol. TB-500, in particular, is often discussed in terms of an initial phase and a subsequent maintenance phase. BPC-157 protocols may involve consistent daily administration for a defined period. The amounts used may differ between phases, and the transition timing depends on patient response.

Patient Response and Tolerance

Individual responses to peptide therapy vary. Some patients respond quickly and may need protocol adjustments sooner. Others may require longer courses or modified approaches. Regular check-ins with your prescribing physician allow for dosing adjustments based on how you are actually responding, rather than relying on a fixed protocol.

Concurrent Medications and Supplements

Other medications or supplements may influence peptide metabolism, clearance, or activity. Your physician should have a complete picture of everything you are taking before designing a dosing protocol.

What the Preclinical Research Shows About Dosing

Most of what we know about BPC-157 and TB-500 dosing comes from animal studies, and translating animal doses to human equivalents is not straightforward.

BPC-157 in Animal Studies

BPC-157 has been studied across a wide range of doses in rodent models without identification of a toxic dose . Effective doses in rats varied by study and condition, and the therapeutic window appears to be wide. Researchers have noted that BPC-157 showed biological activity across multiple orders of magnitude in dosing, which is unusual for a peptide .

TB-500 in Animal Studies

TB-500 (and Thymosin Beta-4) dosing in animal models has similarly varied. Equine studies, which represent some of the earliest applied research on TB-500 for tendon repair, used doses scaled to body weight . Rodent studies have used a range of dosing schedules depending on the injury model.

Why Animal Doses Do Not Translate Directly

Interspecies dose conversion involves more than simple weight scaling. Differences in metabolism, body surface area, peptide clearance rates, and receptor density all complicate the translation. This is one of the core reasons why physician supervision matters: the practitioner draws on clinical experience, emerging data, and patient-specific factors rather than attempting to extrapolate from rat studies.

Protocol Considerations

Frequency

BPC-157 is often administered daily in practitioner-designed protocols. TB-500 administration frequency may vary between the loading and maintenance phases. The specific schedule should be determined by your physician.

Duration

Protocol duration depends on the condition and the patient's response. Common durations discussed in clinical settings range from several weeks to a few months, but there is no clinically validated standard. Some conditions may warrant longer protocols, while others may resolve more quickly.

Reconstitution and Storage

Both BPC-157 and TB-500 typically arrive as lyophilized (freeze-dried) powder that must be reconstituted with bacteriostatic water before use. Proper reconstitution technique, sterile handling, and correct storage (typically refrigerated after reconstitution) are essential for maintaining peptide integrity and safety. Your pharmacy and physician will provide specific instructions.

Injection Technique

Subcutaneous injection is the most common route for both peptides. Proper technique includes using appropriate needle gauge, rotating injection sites, maintaining sterile conditions, and following your provider's instructions exactly. Our BPC-157 how to inject and TB-500 how to inject guides provide more detail on technique.

Safety

The wide therapeutic window observed for BPC-157 in preclinical studies is reassuring from a safety perspective, but it does not eliminate the need for proper dosing guidance . TB-500 (Thymosin Beta-4) has been used in human clinical trials at defined doses with generally mild side effects .

The risks of incorrect dosing include:

• Subtherapeutic levels that fail to produce meaningful results
• Unnecessary expenditure on ineffective protocols
• Potential for unknown effects at doses not studied in any research context
• Contamination risk from using unregulated sources that may have inaccurate concentration labeling

Pharmaceutical-grade peptides from licensed compounding pharmacies, prescribed and supervised by a physician, represent the only responsible approach to this stack.

Frequently Asked Questions

Why don't you list specific doses in this article?

Because there are no FDA-approved or clinically standardized doses for these peptides, and publishing specific numbers could encourage self-dosing without medical oversight. Dosing is individualized and should be determined by a licensed physician who knows your medical history, current health status, and treatment goals.

Can I adjust my own dose based on how I feel?

No. Dose adjustments should always be made in consultation with your prescribing physician. Subjective feelings are one data point, but they do not capture the full picture of what is happening biologically. Your physician may also want to monitor objective markers before modifying your protocol.

Does body weight determine the dose?

Body weight is one factor, but not the only one. The nature of the condition, the administration route, the treatment phase, and individual response all influence the appropriate dosing approach. A physician considers the full picture rather than relying on a single variable.

What happens if I take too much or too little?

Taking too little may simply result in no meaningful benefit. Taking too much introduces uncertainty, because doses beyond those studied in research are, by definition, unstudied in terms of effects and safety. The wide therapeutic window observed in preclinical BPC-157 research is reassuring, but it does not replace the need for medical guidance.

How do I know if my dosage is working?

Your physician will establish metrics for tracking progress, which may include subjective symptom assessment, functional testing, imaging, or other clinical measures depending on your condition. Regular follow-up appointments are essential for evaluating whether the protocol is producing the desired results.